February 2017

Major biotech stocks like Amgen AMGN and Gilead GILD reported fourth quarter results — while both topped estimates, revenue outlook fell short of expectations. Recap of the Week’s Most Important Stories Amgen Delivers Strong Quarter but Sales Guidance Falls Short: Amgen’s fourth quarter results were better-than-expected with the company beating on all fronts. The company […]

by

Cambridge based GW Pharmaceuticals has now been granted Orphan Drug Designation from FDA for Cannabidiol drug to treat a 3rd rare genetic form of epilepsy. GW Pharmaceuticals has been granted Orphan Drug Designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). Epidiolex is a liquid formulation of pure plant-derived CBD, which is in development for […]

by

CV Sciences Inc (OTCMKTS:CVSI) is a micro-cap name that has grabbed hold of the attention of traders during the stock’s progression up the price ladder of late. We covered this one recently, and wanted to update our bullish outlook as the stock breaks higher on rapidly expanding volume. The breakout is significant because of its […]

by

Shares of INSYS Therapeutics, Inc. (NASDAQ:INSY) dropped -6.02% by the end of trading session at $12.03. For the current quarter, the 4 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of 0/share, which would compare with $0.36 in the year-ago quarter. The net percentage change is -28.31% over the last 12 […]

by

Major biotech stocks like Amgen AMGN and Gilead GILD reported fourth quarter results — while both topped estimates, revenue outlook fell short of expectations. Recap of the Week’s Most Important Stories Amgen Delivers Strong Quarter but Sales Guidance Falls Short: Amgen’s fourth quarter results were better-than-expected with the company beating on all fronts. The company […]

by

CV Sciences Inc (OTCMKTS:CVSI) is a penny stock player in the rapidly growing space of synthetic cannabidiol. CVSI stock blasted higher into the November 8 election, but then “Christmas Tree’d” down the chart and settled back where it had started. However, the stock has gotten back into gear of late, and we thought it was […]

by

OTTAWA, ONTARIO–(Marketwired – Feb 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics […]

by

SAN DIEGO, Feb. 6, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment AXIM® Biotechnologies, Inc. (OTC: AXIM) was featured on a CBS New York News segment about the Company’s clinical trials for its CanChew Plus® cannabidiol (CBD) chewing gum for the […]

by

OTTAWA, ONTARIO–(Marketwired – Feb 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and […]

by

Medical Marijuana Inc (OTCMKTS:MJNA) is a central brand in the cannabis patch. The stock has performed very well in this important year for the space. We’ve seen renewed strength in recent weeks with an extra pop late this past week as the company announced that its subsidiary company HempMeds has formed a new business in […]

by